PA5-31401

antibody from Invitrogen Antibodies

Targeting: SPRY4

Western blot (Data presented on provider website)

Immunohistochemistry (Data presented on provider website)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-31401

Provider

Invitrogen Antibodies

Product name

SPRY4 Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Recombinant protein fragment

Description

Recommended positive controls: NT2D1, mouse brain. Predicted reactivity: Mouse (94%), Rat (94%), Sheep (94%), Bovine (95%). Store product as a concentrated solution. Centrifuge briefly prior to opening the vial.

Reactivity

Human, Mouse

Host

Rabbit

Isotype

IgG

Vial size

100 µL

Concentration

1 mg/mL

Storage

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

References

Submitted references

The Role of the miR-21/SPRY2 Axis in Modulating Proangiogenic Factors, Epithelial Phenotypes, and Wound Healing in Corneal Epithelial Cells.

Zhang Y, Yuan F, Liu L, Chen Z, Ma X, Lin Z, Zou J
Investigative ophthalmology & visual science 2019 Sep 3;60(12):3854-3862

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 2 SPRY2 is a direct target of miR-21 in corneal epithelial cells. Corneal epithelial cells were treated with miR-21 inhibitor and exposed to TGF-beta1 (T), 1% O 2 (H), or TGF-beta1 plus 1% O 2 (T+H). The protein levels of SPRY1, SPRY2, SPRY4, and p-ERK, were determined by Western blotting (A) followed by densitometry analysis using ImageJ software (B). Tubulin was used as the loading control. (C) miR-21 and its putative binding sequences in the mouse 3'-UTR of Spry2. The binding sequences in the complementary sites were replaced by the indicated nucleotides to produce mutant Spry2 3'-UTR luciferase reporter constructs. Marked sequences represent the conserved complementary nucleotides of the miR-21 binding sequence in humans and various mammals. (D, E) Luciferase activity of the wild-type and mutated 3'-UTR of Spry2 treated with miR-21 mimic (D) or inhibitor (E). *P < 0.05, **P < 0.01, ***P < 0.001, versus the untreated group (B) or mimic NC (D) or inhibitor NC group (E). Experiments were performed in triplicate.